Jane Street’s Xilio Therapeutics XLO Stock Holding History

Jane Street’s Portfolio XLO Stock Details XLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,006	Closed	-$26.9K	–	13162
2025 Q4	$26.9K	Buy	+3,006	New	+$31.6K	﹤0.01%	10665

Other funds holding XLO

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street's XLO Position: Q1 2026 in Review

Jane Street sold out of Xilio Therapeutics (XLO) in Q1 2026, closing a stake of 3,006 shares — an estimated $26.9K sold.

Jane Street first reported a position in XLO in Q4 2025 and held it in 1 quarter. The position peaked at $26.9K in Q4 2025. 24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

Jane Street reported no remaining Xilio Therapeutics position as of Q1 2026 after selling out during the quarter.
Jane Street sold 3,006 Xilio Therapeutics shares in Q1 2026, an estimated $26.9K.
Jane Street first reported a position in Xilio Therapeutics in Q4 2025 and held it in 1 quarter.
Jane Street's Xilio Therapeutics position peaked at $26.9K in Q4 2025.
24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.